Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry.

"Declarations Ethics approvalThis study is being conducted in accordance with Good Clinical Practice (GCP) guidelines, the International Conference on Harmonization (ICH), the ethical principles established in the Declaration of Helsinki, the law 3301/09, and local guidelines. Personal identification data was kept anonymous. An independent ethics committee approved the protocol and the informed consent form (Comité de Ética Dr Claude Bernard – SARCOVID.20200526.16.PI, June 8, 2020). Consent to participateAll patients signed the corresponding informed consent form to participate in this registry. Consent for publicationIndividuals provided consent for the publication of their data. Conflict of interestThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SAR-COVID is a multi-sponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them participated or influenced the development of the project, data collection, analysis, interpretation, or writing of the report. They do not have access to the information collected in the database. Conflict of interest The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SAR-COVID is a multi-sponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them participated or influenced the development of the project, data collection, analysis, interpretation, or writing of the report. They do not have access to the information collected in the database."

"Funding The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: SAR-COVID, as a strategic registry from the Argentine Society of Rheumatology, has received unrestricted research grants to carry out this project from Pfizer, AbbVie, and Elea Phoenix. In addition, two grants from the International League of Associations of Rheumatology have been obtained."